Ku ya 8 Nzeri 2025, InnoCare Pharma yatangaje ko HIBRUKA (orelabrutinib) yemejwe n'Ikigo gishinzwe ubumenyi bw'ubuzima (HSA) cyo muri Singapuru mu kuvura abarwayi bakuru bafite indwara ya lymphoma yo mu gace k'amajyepfo (R/R MZL) yasubiwemo cyangwa yasubiwemo.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Lymphoma yo mu gace k'imbere (MZL) ni lymphoma yo mu bwoko bwa B-cell non-Hodgkin's lymphoma (NHL) ikora cyane cyane ku barwayi bari mu kigero cyo hagati n'abageze mu za bukuru. Umubare w'abandura MZL buri mwaka uriyongera ku isi. Nyuma yo kuvurwa ku rwego rwa mbere, abarwayi bafite R/R MZL babura uburyo bwiza bwo kuvura.
Muri Mata 2025, orelabrutinib yemerewe mu Bushinwa kuvura abarwayi ba kanseri y’amaraso idakira (CLL) / lymphoma ntoya ya lymphocytic (SLL). Orelabrutinib nayo yemerewe kuvura ibindi bimenyetso bitatu mu Bushinwa, birimo gusubira inyuma no kugabanuka kw’indwara (R/R) CLL/SLL, r/r mantle cell lymphoma (R/R MCL) na r/r marginal zone lymphoma (R/R MZL), byose byashyizwe ku rutonde rw’imiti yo kwishyurwa mu Bushinwa.
Ingufu, Umutekano, n'Ishingiro bya Orelabrutinib Plus Obinutuzumab muri Symological Treatment-Naive Marginal Zone Lymphoma: Inyigo y’icyiciro cy’abashaka kuvura yagaragaje ko mu bushakashatsi bwose no mu gihe cyo kuvura indwara ziterwa n’inyongera, igipimo rusange cy’ubutabazi (ORR) ari 100%. Abarwayi batatu bafite igisubizo cy’igice (PR) nyuma yo kuvura indwara ziterwa n’inyongera babonye igisubizo cyuzuye (CR) mu gihe cyo kubungabungwa.
Isuzuma rya ADCC ryagaragaje ko orelabrutinib hamwe na regimen ya obinutuzumab byatumye ADCC ikora cyane mu miterere y’uturemangingo twa TMD-8 na REC-1.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Indangamuntu ya WeChat: 17801183037
Email：myimmnet@163.com
Igihe cyo kohereza: Nzeri-09-2025